Bafna PharmaceuticalsNSE:BAFNAPH +5.00%59 Pretax Margin % is 6.20% as of Mar. 2026, which is 61% above its 10-year median of 3.84. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 59/100 and a GF Value™ of ₹91.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 50.05% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's Pretax Margin % or its related term are showing as below:
NSE:BAFNAPH'
s Pretax Margin % Range Over the Past 10 Years
Min: -41.93 Med: 3.84 Max: 10.07
Current: 7.28
NSE:BAFNAPH's Pretax Margin % is ranked worse than 50.05% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs NSE:BAFNAPH: 7.28
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bafna Pharmaceuticals Pretax Margin % Related Terms
Bafna Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Pretax Margin % of 6.20% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bafna Pharmaceuticals and its competitors. This is 61% above median its historical median of 3.84. According to the industry distribution chart, Bafna Pharmaceuticals ranks #478 out of 955 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Bafna Pharmaceuticals' Pretax Margin % too high?
Bafna Pharmaceuticals' current Pretax Margin % of 6.20% is 61% above median its 10-year median of 3.84. The Drug Manufacturers industry median Pretax Margin % is 7.28. Bafna Pharmaceuticals' value of 6.20% is 14.8% below this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #478 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #478 out of 955 companies for Pretax Margin %. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Pretax Margin % is 7.28. Bafna Pharmaceuticals' value of 6.20% is 14.8% below this benchmark. While the company's 10-year median is 3.84 vs. the industry median of 7.28, Bafna Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Pretax Margin % of 6.20% is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Pretax Margin % is 6.20%, which is 61% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.79, compared to a current price of ₹194.68 — trading 112.1% above its estimated fair value. The current Pretax Margin % is 6.20%, which is 61% above median its 10-year median of 3.84 and 14.8% below the Drug Manufacturers industry median of 7.28. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Pretax Margin % is 6.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 112.1% above its estimated GF Value™ of ₹91.79.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Pretax Margin %: 6.20% (61% above median its 10-year median of 3.84)
GF Value™: ₹91.79 vs. price of ₹194.68 (112.1% above fair value)
Industry Position: 14.8% below the Drug Manufacturers median (#478 of 955)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
